Luxempart (LUX:LXMPR)
Luxembourg · Delayed Price · Currency is EUR 68.00
+1.00 (1.49%)
At close: Jul 30, 2025
Theseus Pharmaceuticals Revenue
In the year 2024, Luxempart had annual revenue of 50.29M EUR, down -75.58%. Luxempart had revenue of 25.88M in the half year ending December 31, 2024, a decrease of -77.31%.
Revenue
50.29M
Revenue Growth
-75.58%
P/S Ratio
27.24
Revenue / Employee
1.80M
Employees
28
Market Cap
1.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 50.29M | -155.66M | -75.58% |
| Dec 31, 2023 | 205.95M | 138.32M | 204.55% |
| Dec 31, 2022 | 67.62M | -447.48M | -86.87% |
| Dec 31, 2021 | 515.11M | 344.82M | 202.49% |
| Dec 31, 2020 | 170.29M | -48.63M | -22.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reinet Investments S.C.A. | 798.00M |
| CPI FIM | 167.35M |
| Socfinasia | 186.43M |
| Socfinaf | 591.38M |
| Velcan Holdings | 2.95M |
| GP Investments | -8.48M |